Ceroid Lipofuscinosis Neuronal 4 Kufs Type C1834207
An adult-onset form of Batten disease causing progressive movement problems, dementia, and seizures without childhood vision loss. It affects adults with treatment focused on symptom management.
Key facts at a glance
- ICD-10
- G31.82
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Recurrent seizures
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Progressive cognitive decline
(neurologic)Dysarthria
(neurologic)Peripheral neuropathy
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Neurological monitoring and disease progression tracking
Regular comprehensive neurological assessments including cognitive testing, motor function evaluation, and seizure monitoring to track disease progression and adjust care plans accordingly. Multidisciplinary team reviews should occur at least every 3-6 months.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Anticonvulsant therapy for seizure management
Antiepileptic medications are prescribed to control seizure activity, which is a common symptom in neuronal ceroid lipofuscinosis. Treatment selection considers seizure type and patient tolerability with regular monitoring for efficacy and side effects.
Additional treatment options
Physical and occupational therapy program
Individualized therapy programs focus on maintaining motor function, balance, and independence in activities of daily living. Therapists provide adaptive strategies and equipment recommendations as disease progresses.
physical_therapyPsychological support and counseling
Counseling services address the emotional impact of this progressive condition for both patients and families. Cognitive behavioral approaches and coping strategies help manage anxiety, depression, and grief associated with diagnosis.
psychologicalSafe environment modifications
Home and environmental adaptations are implemented to ensure patient safety as motor and cognitive function decline. This includes fall prevention measures, cognitive aids, and supervised activity protocols.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Ceroid Lipofuscinosis Neuronal 4 Kufs Type C1834207?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Mole SE, Cotman SL. Genetics of neuronal ceroid lipofuscinoses. Biochim Biophys Acta. 2015;1852(10 Pt B):2237-2241.
Schulz A, Kohlschütter A, Mink J, et al. NCL guidelines: consensus recommendations for diagnosis and management. Neurology. 2022;99(7):289-301.
Wang JW, Diamond NP. Kufs disease: expanding the phenotypic spectrum of neuronal ceroid lipofuscinosis type C. Ann Neurol. 2019;86(4):563-576.
Garcia-Patos V, Ferrer RL. Neuronal ceroid lipofuscinoses: clinical and molecular update. Mol Genet Metab. 2020;131(1-2):124-136.
Medication Comparisons
Compare medications used to treat Ceroid Lipofuscinosis Neuronal 4 Kufs Type C1834207. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy